Diagnosis of Rhabdomyosarcomas with Particular Reference to Immunohistochemical Markers

  • Richard L. Carter
  • Keith P. McCarthy


Soft tissue sarcomas account for about 6% of all cancers in children and young adults, and at least half of them are rhabdomyosarcomas.1 The age range, sites of origin, morphology, and pathological classification of these tumors have been fully documented2–6 and only a few comments need to be made here.


Soft Tissue Sarcoma Intermediate Filament Rhabdomyosarcoma Cell Embryonal Rhabdomyosarcoma Royal Marsden Hospital 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    International Incidence of Childhood Cancer. IARC Scientific Publications No. 87. Lyon, 1988Google Scholar
  2. 2.
    Bale PM, Parsons RE, Stevens MM: Pathology and behaviour of juvenile rhabdomyosarcoma, in Finegold, M (ed): Pathology of Neoplasia in Children and Adolescents, Philadelphia, W.B. Saunders; 196–222; 1986Google Scholar
  3. 3.
    Shimada H, Newton WA, Soule EH, Beltangady MS, Maurer HM: Pathology of fatal rhabdomyosarcoma. Cancer 59:459–465, 1987PubMedGoogle Scholar
  4. 4.
    Newton WA, Soule EH, Hamoudi AB, et al: Histopathology of childhood sarcomas, Intergroup Rhabdomyosarcoma Studies I and II: clinicopathologic correlation. J Clin Oncol 6:67–75, 1988PubMedGoogle Scholar
  5. 5.
    Rodary C, Rey A, Olive D, et al: Prognostic factors in 281 children with nonmetastatic rhabdomyosarcoma (RMS) at diagnosis. Med Ped Oncol 16:71–77, 1988Google Scholar
  6. 6.
    Enzinger FM, Weiss SW: Soft Tissue Tumors, 448–488. St. Louis, C.V. Mosby, 1988Google Scholar
  7. 7.
    Horn RC, Enterline HT: Rhabdomyosarcoma: A clinico-pathological study of 39 cases. Cancer 11:181–199, 1958PubMedGoogle Scholar
  8. 8.
    Caillaud JM, Gerard-Marchant R, Marsden HB, et al: Histopathological classification of childhood rhabdomyosarcoma: A report from the International Society of Pediatric Oncology Pathology Panel. Med Ped Oncol 17:391–400, 1989Google Scholar
  9. 9.
    Molenaar WM, Oosterhuis JW, Kamps WA: Cytologic “differentiation” in childhood rhabdomyosarcomas following polychemotherapy. Hum Pathol 15:973–979, 1984PubMedGoogle Scholar
  10. 10.
    Takizawa T, Matsui T, Maeda Y, et al: X-radiation-induced differentiation of xenotransplanted human undifferentiated rhabdomyosarcoma. Lab Invest 60:22–29, 1989PubMedGoogle Scholar
  11. 11.
    Mierau GW, Berry PJ, Orsini EN: Small round cell neoplasms: Can electron microscopy and im-munohistochemical studies accurately classify them? Ultrastruct Pathol 9:99–111, 1985PubMedGoogle Scholar
  12. 12.
    Erlandson RA: The ultrastructural distinction between rhabdomyosarcoma and other undifferentiated “sarcomas.” Ultrastruct Pathol 11:83–101, 1987PubMedGoogle Scholar
  13. 13.
    Mierau GW, Favara BE: Rhabdomyosarcoma in children. Cancer 46:2035–2040, 1980PubMedGoogle Scholar
  14. 14.
    Bundtzen JL, Norback DH: The ultrastructure of poorly differentiated rhabdomyosarcomas. Hum Pathol 13:301–313, 1982PubMedGoogle Scholar
  15. 15.
    Triche TJ, Askin FB, Kissane JM: Neuroblastoma, Ewing’s sarcoma, and the differential diagnosis of small-, round-, blue-cell tumors, in Finegold, M (ed): Pathology of Neoplasia in Children and Adolescents, Philadelphia, W.B. Saunders; 1986Google Scholar
  16. 16.
    Dickman PS, Triche TJ: Extraosseous Ewing’s sarcoma versus primitive rhabdomyosarcoma: Diagnostic criteria and clinical correlation. Hum Pathol 17:881–893, 1986PubMedGoogle Scholar
  17. 17.
    Alberts B, Bray D, Lewis J, Roff M, Roberts K, Watson JD: Molecular Biology of the Cell, 2nd ed 613–680. New York, Garland Publishing, 1989Google Scholar
  18. 18.
    Kemshead JT, Fritschy J, Goldman A, Malpas JS, Pritchard J: Use of panels of monoclonal antibodies in the differential diagnosis of neuroblastoma and lymphoblastic disorders. Lancet 1:12–15, 1983PubMedGoogle Scholar
  19. 19.
    Darbyshire PJ, Bourne SP, Allan PM, et al: The use of a panel of monoclonal antibodies in pediatric oncology. Cancer 59:726–730, 1987PubMedGoogle Scholar
  20. 20.
    Oppedal BR, Brandtzaeg P, Kemshead JT: Immunohistochemical differentiation of neuroblastomas from other small round cell neoplasms of childhood using a panel of mono- and polyclonal antibodies. Histopathology 11:363–374, 1987PubMedGoogle Scholar
  21. 21.
    Pilkington GR, Pallesen G: Phenotypic characterization of non-haemopoietic small cell tumors of childhood with monoclonal antibodies to leucocytes, epithelial cells and cytoskeletal proteins. Histopathology 14:347–357, 1989PubMedGoogle Scholar
  22. 22.
    Erlandson RA: Diagnostic immunohistochemistry of human tumors. Am J Surg Pathol 8:615–624, 1984PubMedGoogle Scholar
  23. 23.
    Mukai K, Rosai J, Hallaway BE: Localization of myoglobin in normal and neoplastic human skeletal muscle cells using an immunoperoxidase method. Am J Surg Pathol 3:373–376, 1979PubMedGoogle Scholar
  24. 24.
    Corson JM, Pinkus GS: Intracellular myoglobin— a specific marker for skeletal muscle differentiation in soft tissue sarcomas. Am J Pathol 103:384–389, 1981PubMedGoogle Scholar
  25. 25.
    Kindblom L-G, Seidal T, Karlsson K: Immuno-histochemical localization of myoglobin in human muscle tissue and embryonal and alveolar rhabdomyosarcoma. Acta Path Microbiol Immunol Scand Sect A 90:167–174, 1982Google Scholar
  26. 26.
    Brooks J J: Immunohistochemistry of soft tissue tumors: Myoglobin as a tumor marker for rhabdomyosarcoma. Cancer 50:1757–1763, 1982PubMedGoogle Scholar
  27. 27.
    Kagawa N, Sano T, Inaba H, Mori K, Hizawa K: Immunohistochemistry of myoglobin in rhabdomyosarcomas. Acta Pathol Jpn 33:515–522, 1983PubMedGoogle Scholar
  28. 28.
    Tsokos M, Howard R, Costa J: Immunohistochemical study of alveolar and embryonal rhabdomyosarcoma. Lab Invest 48:148–155, 1983PubMedGoogle Scholar
  29. 29.
    Kahn HJ, Yeger H, Kassim O, et al: Immunohisto- chemical and electron microscopic assessment of childhood rhabdomyosarcoma: Increased frequency of diagnosis over routine histologic methods. Cancer 51:1897–1903, 1983PubMedGoogle Scholar
  30. 30.
    de Jong ASH, van Vark M, Albus-Lutter CE, van Raamsdonk W, Voute PA: Myosin and myoglobin as tumor markers in the diagnosis of rhabdomyosarcoma: A comparative study. Am J Surg Pathol 8:521–528, 1984PubMedGoogle Scholar
  31. 31.
    Eusebi V, Ceccarelli C, Gorza L, Schiaffino S, Bussolati G: Immunocytochemistry of rhabdomyosarcoma: The use of four different markers. Am J Surg Pathol 10:293–299, 1986PubMedGoogle Scholar
  32. 32.
    Scupham R, Gilbert EF, Wilde J, Wiedrich TA: Immunohistochemical studies of rhabdomyosarcoma. Arch Pathol Lab Med 110:818–821, 1986PubMedGoogle Scholar
  33. 33.
    Schmidt D, Reimann O, Treuner J, Harms D: Cellular differentiation and prognosis rhabdomyosarcoma. Virchows Arch [Pathol Anat] 409:183–194, 1986Google Scholar
  34. 34.
    Coindre J-M, de Mascarel A, Trojani M, de Mascarel I, Pages A: Immunohistochemical study of rhabdomyosarcoma. Unexpected staining with S100 protein and cytokeratin. J Pathol 155:127–132, 1988PubMedGoogle Scholar
  35. 35.
    Dodd S, Malone M, McCulloch W: Rhabdomyo sarcoma in children: A histological and immunohistochemical study of 59 cases. J Pathol 158:13–18, 1989PubMedGoogle Scholar
  36. 36.
    Carter RL, McCarthy KP, Machin LG, Jameson CF, Philp ER, Pinkerton CR: Expression of desmin and myoglobin in rhabdomyosarcomas and in developing skeletal muscle. Histopathology 15:585–595, 1989PubMedGoogle Scholar
  37. 37.
    Carter RL, Jameson CF, Philp ER, Pinkerton CR: Comparative phenotypes in rhabdomyosarcomas and developing skeletal muscle. Histopathology 17:301–309, 1990PubMedGoogle Scholar
  38. 38.
    Eusebi V, Bondi A, Rosai J: Immunohistochemical localization of myoglobin in nonmuscular cells. Am J Surg Pathol 8:51–55, 1984PubMedGoogle Scholar
  39. 39.
    Caplan AI, Fiszman MY, Eppenberger HM: Molecular and cell isoforms during development. Science 221:921–927, 1983PubMedGoogle Scholar
  40. 40.
    Whalen RG, Sell SM, Butler-Browne GS, Schwartz K, Bouveret P, Pinset-Harstrom I: Three myosin heavy-chain isozymes appear sequentially in rat muscle development. Nature 292:805–809, 1981PubMedGoogle Scholar
  41. 41.
    Strohman RC, Micou-Eastwood J, Glass CA, Matsuda R: Human fetal muscle and cultured myotubes derived from it contain a fetal-specific myosin light chain. Science 221:955–957, 1983PubMedGoogle Scholar
  42. 42.
    Biral D, Damiani E, Margreth A, Scarpini E: Myosin subunit composition in human developing muscle. Biochem J 224:923–931, 1984PubMedGoogle Scholar
  43. 43.
    Billeter R, Weber H, Lutz H, Howald H, Eppenberger HM, Jenny E: Myosin types in human skeletal muscle fibers. Histochemistry 65:249–259, 1980PubMedGoogle Scholar
  44. 44.
    Koh S-J, Johnson WW: Antimyosin and antirhab-domyoblast sera: Their use for the diagnosis of childhood rhabdomyosarcoma. Arch Pathol Lab Med 104:118–122, 1980PubMedGoogle Scholar
  45. 45.
    Eusebi V, Rilke F, Ceccarelli C, Fedeli F, Schiaffino S, Bussolati G: Fetal heavy chain skeletal myosin. Am J Surg Pathol 10:680–686, 1986PubMedGoogle Scholar
  46. 46.
    Schiaffino S, Gorza L, Sartore S, Saggin L, Carli M: Embryonic myosin heavy chain as a differentiation marker of developing human skeletal muscle and rhabdomyosarcoma. A monoclonal antibody study. Exp Cell Res 163:211–220, 1986PubMedGoogle Scholar
  47. 47.
    Mukai K, Schollmeyer JV, Rosai J: Immunohisto-chemical localization of actin. Applications in surgical pathology. Am J Surg Pathol 5:91–97, 1981PubMedGoogle Scholar
  48. 48.
    de Jong ASH, van Kessel-van Vark M, Albus Lutter CE, van Raamsdonk W, Voute PA: Skeletal muscle actin as tumor marker in the diagnosis of rhabdomyosarcoma in childhood. Am J Surg Pathol 9:467–474, 1985PubMedGoogle Scholar
  49. 49.
    Skalli O, Gabbiani G, Babai F, Seemayer TA, Pizzolato G, Schurch W: Intermediate filament proteins and actin isoforms as markers for soft tissue tumor differentiation and origin. II. Rhabdomyosarcomas. Am J Pathol 130:515–531, 1988Google Scholar
  50. 50.
    Schmidt RA, Cone R, Haas JE, Gown AM: Diagnosis of rhabdomyosarcomas with HHF35, a monoclonal antibody directed against muscle actins. Am J Pathol 131:19–28, 1988PubMedGoogle Scholar
  51. 51.
    Mukai M, Iri H, Torikata C, Kageyama K, Morikawa Y, Shimizu K: Immunoperoxidase demonstration of a new muscle protein (Z-protein) in myogenic tumors as a diagnostic aid. Am J Pathol 114:164–170, 1984PubMedGoogle Scholar
  52. 52.
    Osborn M, Hill C, Altmannsberger M, Weber K: Monoclonal antibodies to titin in conjunction with antibodies to desmin separate rhabdomyosarcomas from other tumor types. Lab Invest 55:101–108, 1986PubMedGoogle Scholar
  53. 53.
    Variend S, Loughlin MA: An evaluation of enzyme histochemistry in the diagnosis of childhood rhabdomyosarcoma. Histopathology 9:389–400, 1985PubMedGoogle Scholar
  54. 54.
    Staal GEJ, Rijksen G, van Oirschot BA, Roholl PJM: Characterization of pyruvate kinase from human rhabdomyosarcoma in relation to immunohistochemical and morphological criteria. Cancer 63:479–483, 1989PubMedGoogle Scholar
  55. 55.
    Wold LE, Li C-Y, Homburger HA: Localization of the B and M polypeptide subunits of creatine kinase in normal and neoplastic human tissues by an immunoperoxidase technic. Am J Clin Pathol 75:327–332, 1981PubMedGoogle Scholar
  56. 56.
    de Jong ASH, van Kessel-van Vark M, Albus Lutter CE, Voute PA: Creatine kinase subunits M and B as markers in the diagnosis of poorly differentiated rhabdomyosarcomas in children. Hum Pathol 16:924–928, 1985PubMedGoogle Scholar
  57. 57.
    Osborn M, Geisler N, Shaw G, Sharp G, Weber K: Intermediate filaments. Cold Spring Harbor Symp Quant Biol 46:413–429, 1982PubMedGoogle Scholar
  58. 58.
    Osborn M, Weber K: Tumor diagnosis by intermediate filament typing: a novel tool for surgical pathology. Lab Invest 48:372–394, 1983PubMedGoogle Scholar
  59. 59.
    Gabbiani G, Kapanci Y, Barazzone P, Franke WW: Immunochemical identification of intermediate-sized filaments in human neoplastic cells. A diagnostic aid for the surgical pathologist. Am J Pathol 104:206–216, 1981PubMedGoogle Scholar
  60. 60.
    Denk H, Krepier R, Artlieb U, et al: Proteins of intermediate filaments. An immunohistochemical and biochemical approach to the classification of soft tissue tumors. Am J Pathol 110:193–208, 1983PubMedGoogle Scholar
  61. 61.
    Altmannsberger M, Osborn M, Treuner J, Holscher A, Weber K, Schauer A: Diagnosis of human childhood rhabdomyosarcoma by antibodies to desmin, the structural protein of muscle specific intermediate filaments. Virchows Arch [Cell Pathol] 39:203–215, 1982Google Scholar
  62. 62.
    Miettinen M, Lehto V-P, Badley RA, Virtanen I: Expression of intermediate filaments in soft-tissue sarcomas. Int J Cancer 30:541–546, 1982PubMedGoogle Scholar
  63. 63.
    Miettinen M, Lehto V-P, Badley RA, Virtanen I: Alveolar rhabdomyosarcoma. Demonstration of the muscle type of intermediate filament protein, desmin, as a diagnostic aid. Am J Pathol 108:246–251, 1982PubMedGoogle Scholar
  64. 64.
    Altmannsberger M, Weber K, Droste R, Osborn M: Desmin is a specific marker for rhabdomyosarcomas of human and rat origin. Am J Pathol 118:85–95, 1985PubMedGoogle Scholar
  65. 65.
    Dias P, Kumar P, Marsden HB, et al: Evaluation of desmin as a diagnostic and prognostic marker of childhood rhabdomyosarcomas and embryonal sarcomas. Br J Cancer 56:361–365, 1987PubMedGoogle Scholar
  66. 66.
    Molenaar WM, Oosterhuis JW, Oosterhuis AM, Ramaekers FCS: Mesenchymal and muscle-specific intermediate filaments (vimentin and desmin) in relation to differentiation in childhood rhabdomyosarcomas. Hum Pathol 16:838–843, 1985PubMedGoogle Scholar
  67. 67.
    Gould VE: The coexpression of distinct classes of intermediate filaments in human neoplasms. Arch Pathol Lab Med 109:984–985, 1985PubMedGoogle Scholar
  68. 68.
    Damjanov I: Antibodies to intermediate filaments and histogenesis (editorial). Lab Invest 47:215–217, 1982PubMedGoogle Scholar
  69. 69.
    Azumi N, Battifora H: The distribution of vimentin and keratin in epithelial and nonepithelial neoplasms. A comprehensive immunohistochemical study on formalin- and alcohol-fixed tumors. Am J Clin Pathol 88:286–296, 1987PubMedGoogle Scholar
  70. 70.
    Coggi G, Dell’Orto P, Braidotti P, Coggi A, Viale G: Coexpression of intermediate filaments in normal and neoplastic human tissues: A reappraisal. Ultrastruct Pathol 13:501–514, 1989PubMedGoogle Scholar
  71. 71.
    Miettinen M, Rapola J: Immunohistochemical spectrum of rhabdomyosarcoma and rhabdomyo-sarcoma-like tumors. Expression of cytokeratin and the 68-kD neurofilament protein. Am J Surg Pathol 13:120–132, 1989PubMedGoogle Scholar
  72. 72.
    Tsokos M, Linnoila RI, Chandra RS, Triche TJ: Neuron-specific enolase in the diagnosis of neuroblastoma and other small, round-cell tumors in children. Hum Pathol 15:575–584, 1984PubMedGoogle Scholar
  73. 73.
    Carter RL, Al-Sam SZ, Corbett RP, Clinton S: A comparative study of immunohistochemical staining for neuron-specific enolase, protein gene product 9.5 and S-100 protein in neuroblastoma, Ewing’s sarcoma and other round cell tumours in children. Histopathology 16:461–467, 1990PubMedGoogle Scholar
  74. 74.
    Cordell JL, Falini B, Erber WN, et al: Immunoen-zymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 32:219–229, 1984PubMedGoogle Scholar
  75. 75.
    Patton RB, Horn RC: Rhabdomyosarcoma: Clinical and pathological faetures and comparison with human fetal and embryonal skeletal muscle. Surgery 52:572–584, 1962PubMedGoogle Scholar
  76. 76.
    Bignami A, Dahl D: Early appearance of desmin, the muscle-type intermediate filament protein, in the rat embryo. J Histochem Cytochem 32:473–476, 1984PubMedGoogle Scholar
  77. 77.
    van Muijen GNP, Ruiter DJ, Warnaar SO: Coexpression of intermediate filament polypeptides in human fetal and adult tissues. Lab Invest 57:359–369, 1987PubMedGoogle Scholar
  78. 78.
    Kagen LJ, Christian CL: Immunologic measurements of myoglobin in human adult and fetal skeletal muscle. Am J Physiol 211:656–660, 1966PubMedGoogle Scholar
  79. 79.
    Gauthier GF, Lowey S, Hobbs AW: Fast and slow myosin in developing muscle fibers. Nature 274:25–29, 1978PubMedGoogle Scholar
  80. 80.
    Rubinstein NA, Holtzer H: Fast and slow muscles in tissue culture synthesise only fast myosin. Nature 280:323–325, 1979PubMedGoogle Scholar
  81. 81.
    Granger BL, Lazarides E: Desmin and vimentin coexist at the periphery of the myofibril Z disc. Cell 18:1053–1063, 1979PubMedGoogle Scholar
  82. 82.
    Bennett GS, Fellini SA, Toyama Y, Holtzer H: Redistribution of intermediate filament subunits during skeletal myogenesis and maturation in vitro. J Cell Biol 82:577–584, 1979PubMedGoogle Scholar
  83. 83.
    Gard DL, Lazarides E: The synthesis and distribution of desmin and vimentin during myogenesis in vitro. Cell 19:263–275, 1980PubMedGoogle Scholar
  84. 84.
    Tokuyasu KT, Mäher PA, Singer SJ: Distributions of vimentin and desmin in developing chick myotubes in vivo. I. Immunofluorescence study. J Cell Biol 98:1961–1972, 1984PubMedGoogle Scholar
  85. 85.
    Tokuyasu KT, Mäher PA, Singer SJ: Distributions of vimentin and desmin in developing chick myotubes in vivo. II. Immunoelectron microscopic study. J Cell Biol 100:1157–1166, 1985PubMedGoogle Scholar
  86. 86.
    Trent JM, Meltzer PS, Thompson FH, Casper JT, Fogh JE: Nonrandom chromosome alterations in rhabdomyosarcoma (RMS): Possible association with a RAS-related oncogene. Proc Annu Meet Am Assoc Cancer Res 25:66, 1984Google Scholar
  87. 87.
    Garvin AJ, Stanley WS, Bennett DD, Sullivan JL, Sens DA: The in vitro growth, heterotransplantation and differentiation of a human rhabdomyosarcoma cell line. Am J Pathol 125:208–217, 1986PubMedGoogle Scholar
  88. 88.
    Douglass EC, Valentine M, Etcubanas E, et al: A specific chromosomal abnormality in rhabdomyosarcoma. Cytogenet Cell Genet 45:148–155, 1987PubMedGoogle Scholar
  89. 89.
    Koufos A, Hansen MF, Copeland NG, Jenkins NA, Lampkin BC, Cavanee WK: Loss of heterozygosity in 3 embryonal tumors suggests a common pathogenetic mechanism. Nature 316:330–334, 1985PubMedGoogle Scholar
  90. 90.
    Scrable HJ, Witte DP, Lampkin BC, Cavanee WK: Chromosomal localisation of the human rhabdomyosarcoma locus by mitotic recombination mapping. Nature 329:645–647, 1987PubMedGoogle Scholar
  91. 91.
    Henry I, Grandjouan S, Couillin P, et al: Tumor-specific loss of 1 lp 15.5 alleles in del 1 lpl3 Wilms tumor and in familial adrenocortical carcinoma. Proc Natl Acad Sei USA 86:3247–3251, 1989Google Scholar
  92. 92.
    Gessler M, Poustka A, Cavanee W, Neve RL, Orkin SH, Bruns GAP: Homozygous deletion in Wilms tumors of a zinc-finger gene identified by chromosome jumping. Nature 343:774–778, 1989Google Scholar
  93. 93.
    Kouzarides T, Ziff E: Behind the FOS and JUN leucine zipper. Cancer Cells 1:71–75, 1989PubMedGoogle Scholar
  94. 94.
    Garson JA, Clayton J, Mclntyre P, Kemshead JT: N-MYC oncogene amplification in rhabdomyosarcoma at release. Lancet 1:1496, 1986PubMedGoogle Scholar
  95. 95.
    Mitani K, Kurosawa H, Suzuki A, et al: Amplification of N-MYC in a rhabdomyosarcoma. Jpn J Cancer Res 77:1062–1065, 1986PubMedGoogle Scholar
  96. 96.
    Tsuda H, Shimosato Y, Upton MP, et al: Retrospective study on amplification of N-MYC and C-MYC genes in paediatric solid tumors and its association with prognosis and tumor differentiation. Lab Invest 59:321–327, 1988PubMedGoogle Scholar
  97. 97.
    Rosson D, Tereba A: Transforming N-RAS genes have been identified in 3 childhood rhabdomyosarcomas and 1 Wilms’ tumor. Proc Annu Meet Am Assoc Cancer Res 25:71, 1984Google Scholar
  98. 98.
    Chardin P, Yeramian P, Madaule P, Tavitian A: N-Ras activation in the RD human rhabdomyosarcoma cell line. Int J Cancer 35:647–652, 1985PubMedGoogle Scholar
  99. 99.
    Stratton MR, Fisher C, Gusterson BA, Cooper CS: Detection of point mutations in N-RAS and K-RAS genes of human embryonal rhabdomyosarcoma using oligonucleotide probes and PCR. Cancer Res 49:6324–6327, 1989PubMedGoogle Scholar
  100. 100.
    Rosen N, Bolen JB, Schwartz AM, Cohen P, De-Seau V, Israel MA: Analysis of pp60 (c-SRC) protein kinase activity in human tumor cell lines and tissues. J Biol Chem 261:13754–13759, 1986PubMedGoogle Scholar
  101. 101.
    Comoglio PM, Naldini L, Renzo FD, Cirillo D, Giordano S: Phosphotyrosine antibodies: a probe for class 1 oncogene products expressed in human malignancies (Meeting abstract). Biotech RIA 86. International symposium on monoclonals and DNA probes in diagnostic and preventive medicine. April 8–10, 1986, Florence, Italy, 38, 1986Google Scholar
  102. 102.
    Stratton MR, Williams S, Fisher C, et al: Structuralalterations of the RB-1 gene in human soft tissue tumors. Br J Cancer 60:202–205, 1989PubMedGoogle Scholar
  103. 103.
    Schweigerer L, Neufeld G, Mergia A, Abraham JA, Fiddes JC, Gospodarowicz D: Basic fibroblast growth factor in human rhabdomyosarcoma cells: Implications for the proliferation and neovasculari-sation of myoblast-derived tumors. Proc Natl Acad Sei USA 84:842–846, 1987Google Scholar
  104. 104.
    Chan HS, Thorner P, Haddad G, Gallie BL: Immu-nohistochemically identified P-glycoprotein correlates with adverse outcome in childhood soft tissue sarcoma. Proc Annu Meet Am Assoc Cancer Res 30:A2028, 1989Google Scholar
  105. 105.
    Goldstein L, Galski H, Fojo A, et al: Expression of a multidrug-resistance gene in human tumors. Proc Annu Meet Am Assoc Cancer Res 29: A1184, 1988Google Scholar
  106. 106.
    Scrable H, Witte D, Shimada H, et al: The molecular differential pathology of rhabdomyosarcoma. Genes Chromosomes Cancer 1:23–35, 1989PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • Richard L. Carter
  • Keith P. McCarthy

There are no affiliations available

Personalised recommendations